Field sales force model to increase adoption of a novel tuberculosis diagnostic test among private providers
Evidence from India
Bibliographic Data
| ID | 21878894 |
|---|---|
| Authors | Sarang Deo (0000-0002-3233-6014, Indian School of Business, corresponding author), Pankaj Jindal (Indian School of Business), Manisha Sabharwal (0009-0004-7633-2244, Clinton Health Access Initiative, New Delhi, India), Aparna Parulkar (Clinton Health Access Initiative, New Delhi, India), Ritu Singh (0000-0002-6384-1320, Clinton Health Access Initiative, New Delhi, India), Rigveda Kadam (0000-0002-2299-5630, Clinton Health Access Initiative, New Delhi, India), Harkesh Dabas (0009-0006-0219-3282, Clinton Health Access Initiative, New Delhi, India), Puneet Dewan (0000-0001-5798-300X, Gates Foundation) |
| Year | 2020 |
| Volume | 5 |
| Issue | 12 |
| Pages | e003600 |
| Publication date | 2020-12-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMJ Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2059-7908 • E-ISSN: 2059-7908 |
| Publisher | BMJ (PUBLISHER • GB) |
| DOI | 10.1136/bmjgh-2020-003600 |
| PMID | 33376100 |
| OpenAlex | W3116316596 |
| Language | EN |
| Citations received | 1 |
| References cited | 39 |
BACKGROUND: Impact of novel high-quality tuberculosis (TB) tests such as Xpert MTB/RIF has been limited due to low uptake among private providers in high-burden countries including India. Our objective was to assess the impact of a demand generation intervention comprising field sales force on the uptake of high-quality TB tests by providers and its financial sustainability for private labs in the long run. METHODS: We implemented a demand generation intervention across five Indian cities between October 2014 and June 2016 and compared the change in the quantity of Xpert cartridges ordered by labs in these cities from before (February 2013-September 2014) to after intervention (October 2014-December 2015) to corresponding change in labs in comparable non-intervention cities. We embedded this difference-in-differences estimate within a financial model to calculate the internal rate of return (IRR) if the labs were to invest in an Xpert machine with or without the demand generation intervention. RESULTS: The intervention resulted in an estimated 60 additional Xpert cartridges ordered per lab-month in the intervention group, which yielded an estimated increase of 11 500 tests over the post-intervention period, at an additional cost of US$13.3-US$17.63 per test. Further, we found that investing in this intervention would increase the IRR from 4.8% to 5.5% for hospital labs but yield a negative IRR for standalone labs. CONCLUSIONS: Field sales force model can generate additional demand for Xpert at private labs, but additional strategies may be needed to ensure its financial sustainability
Business · Tuberculosis · Antibiotic Use and Resistance · Medicine · Nursing · Pharmaceutical Economics and Policy · Tuberculosis Research and Epidemiology
| Citations per year | 1 |
|---|---|
| Citation span | 2025 - 2025 (1) |
| Highly cited | No |